Compare FDUS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDUS | ARVN |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.6M | 781.0M |
| IPO Year | 2011 | 2018 |
| Metric | FDUS | ARVN |
|---|---|---|
| Price | $17.84 | $12.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 21 |
| Target Price | ★ $21.17 | $15.71 |
| AVG Volume (30 Days) | 267.4K | ★ 706.7K |
| Earning Date | 05-29-2026 | 05-27-2026 |
| Dividend Yield | ★ 12.05% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ 2.08 | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $6.01 | N/A |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | $8.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.41 | $5.90 |
| 52 Week High | $22.09 | $14.22 |
| Indicator | FDUS | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 42.75 |
| Support Level | $17.41 | $11.07 |
| Resistance Level | $20.45 | $12.62 |
| Average True Range (ATR) | 0.48 | 0.70 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 31.75 | 18.86 |
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.